GlaxoSmithkline Pharmaceuticals to focus on differential strategy: To forge India Specific Alliance

0
1178

Feb 4, 2013: GlaxoSmithkline Pharmaceuticals which was recently in news for wrong reasons for a case involving cervical cancer vaccines is set to forge an India specific alliance with a multinational company for a new product. The deal is expected to be announced in a few months from now according to Dr. Hasit Joshipura, Managing Director, GSK Pharma. The company has been following a differential strategy in developing countries by providing medicines at “customised pricing” and according to them there is an understanding that Indian market is different and it needs to be treated differently.

GSK has recently re-organised global structure of the parent company by giving importance to the local market of India and by niche products through in licensing deals with other drug manufacturers.